Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.41 |
| ▸ | JAK3 | P52333 | 6/20 | 0.41 |
| ▸ | MOK | Q9UQ07 | 4/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4530249 | 0.82 | JAK2 (0.48) | JAK2JAK3MOKALDH1A1TSHR | |
| SCHEMBL4529962 | 0.80 | HDAC8 (0.52) | — | |
| SCHEMBL4631827 | 0.78 | JAK2 (0.42) | JAK2JAK3MOKPPARGPPARA | |
| SCHEMBL4537056 | 0.76 | ROCK2 (0.51) | ALDH1A1TSHRMAPK1NPSR1 | |
| SCHEMBL4522473 | 0.76 | ROCK2 (0.51) | ALDH1A1TSHRMAPK1NPSR1 | |
| SCHEMBL14338279 | 0.75 | JAK2 (0.56) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL14338306 | 0.74 | JAK2 (0.69) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL4525873 | 0.74 | ALDH1A1 (0.37) | MOKPPARGPPARAALDH1A1TSHR | |
| SCHEMBL4374376 | 0.72 | JAK2 (0.61) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL4374373 | 0.72 | JAK2 (0.61) | JAK2JAK3JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | JAK2 573/4885JAK3 345/4885MOK 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.